HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $20 price target.
September 26, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has received a reiterated 'Buy' rating and a maintained $20 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained $20 price target by HC Wainwright & Co. indicates a positive outlook for Coherus BioSciences. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100